Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1832)	10/3/2007 4:22:52 PM
From: tuck	Respond to of 2240

>>2nd UPDATE: J&J Reports Positive Results For Psoriasis Drug Last update: 10/3/2007 3:00:57 PM (Updated to add details throughout; updates stock price.) By Peter Loftus Of DOW JONES NEWSWIRES An experimental Johnson & Johnson (JNJ) drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study. J&J is developing ustekinumab, also known as CNTO 1275, as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment. Analysts view ustekinumab as a potential supplement to J&J's existing anti-inflammatory drug Remicade. Morgan Stanley has estimated that combined sales of Remicade, ustekinumab and a related experimental drug could exceed $5 billion in 2011. J&J's 2006 Remicade sales were $3 billion. J&J has said it expects to file for regulatory approval of ustekinumab as a psoriasis treatment by the end of this year. Existing treatments for psoriasis include biologic drugs such as Amgen Inc.'s (AMGN) Enbrel and J&J's Remicade. Abbott Laboratories (ABT) has applied for regulatory approval of its Humira anti-inflammatory drug as a treatment for psoriasis. They are part of a category known as anti-TNFs, and some are also approved to treat other diseases including inflammatory-bowel diseases. In a study of about 1,230 patients, more than two-thirds of those taking ustekinumab achieved at least a 75% reduction in psoriasis at week 12 of treatment. Among those taking fake medication, or placebo, only 4% achieved the 75% reduction. The data were presented Wednesday at the World Congress of Dermatology in Buenos Aires. "That brings new hope to a wide variety of patients who may be underserved by current therapies," Craig Leonardi, a researcher from St. Louis University Medical School, said Wednesday at a press conference that was shown live on the Internet. Ustekinumab is a self-injectable biologic that can be given less frequently than Enbrel. Remicade is given as a two-hour intravenous infusion at a doctor's office. In the study, similar rates of adverse events were reported for the drug and placebo groups. Adverse events included injection-site irritation. Abbott is developing its own experimental drug, ABT-874, that targets the same proteins as the J&J compound. On Monday, Abbott said a mid-stage study of ABT-874 showed that a majority of patients who initially responded to treatment maintained a high level of response following discontinuation of therapy. J&J shares rose 3 cents to $66.08 Wednesday afternoon. -By Peter Loftus, Dow Jones Newswires; +1-215-656-8289; peter.loftus@dowjones.com << Cheers, Tuck